Cohort characteristics
| Age group, years . | n (male/female) . | HCMV IgG+, n (%) . | HCMV IgG titer, IU/mL, median (range) . | EBV nuclear antigen IgG+, n (%) . | EBV nuclear antigen IgG titer, IU/mL, median (range) . | NKG2C genotype, n (%)* . | ||
|---|---|---|---|---|---|---|---|---|
| +/+ . | +/− . | −/− . | ||||||
| 1-2 | 23 (9/14) | 20 (86.9) | 487.5 (81.8-845.2)† | 12 (52.2) | 107.0 (48.5-178.6) | 11 (47.8) | 10 (43.4) | 2 (8.7) |
| 3-5 | 19 (6/13) | 18 (94.7) | 288.4 (80.9-1681.8) | 13 (68.4) | 134.0‡ (32.5-328.7) | 7 (37.8) | 10 (52.6) | 2 (10.5) |
| 6-9 | 18 (11/7) | 18 (100) | 361.1 (89.2-2200.2)¶ | 16 (88.9) | 103.6 (33.1-219.7) | 8 (47.0) | 7 (41.2) | 2 (11.8) |
| 10-12 | 20 (10/10) | 20 (100) | 215.4 (43.4-1693.6) | 18 (90.0) | 119.3§ (37.2-359.5) | 8 (44.4) | 8 (44.4) | 2 (11.1) |
| 13-15 | 23 (10/13) | 23 (100) | 252.6 (51.5 −1057.9) | 16 (70.0) | 114.6 (29.7-193.4) | 11 (47.8) | 10 (43.4) | 2 (8.7) |
| 16-19 | 23 (11/12) | 23 (100) | 177.6 (61.2-678.1) | 18 (78.2) | 99.9 (23.9-195.2) | 10 (47.6) | 8 (38.1) | 3 (14.3) |
| 20-25 | 22 (11/11) | 22 (100) | 252.5 (81.5-828.4) | 19 (86.4) | 93.9 (27.6-171.7) | 11 (52.4) | 8 (38.1) | 2 (9.5) |
| 26-39 | 22 (13/9) | 22 (100) | 165.9 (39.0-968.4) | 19 (86.4) | 88.8 (24.9-272.7) | 14 (73.7) | 3 (15.7) | 2 (10.5) |
| 40-49 | 21 (10/11) | 21 (100) | 191.2 (53.5-735.2) | 13 (61.9) | 73.4 (24.0-183.2) | 14 (70.0) | 4 (20.0) | 2 (10.0) |
| Total | 191 (91/100) | 187 (97.9) | 252.6 (39-2200.1) | 145 (75.9) | 101.8 (23.9-359.5) | 94 (51.9) | 68 (37.6) | 19 (10.5) |
| Age group, years . | n (male/female) . | HCMV IgG+, n (%) . | HCMV IgG titer, IU/mL, median (range) . | EBV nuclear antigen IgG+, n (%) . | EBV nuclear antigen IgG titer, IU/mL, median (range) . | NKG2C genotype, n (%)* . | ||
|---|---|---|---|---|---|---|---|---|
| +/+ . | +/− . | −/− . | ||||||
| 1-2 | 23 (9/14) | 20 (86.9) | 487.5 (81.8-845.2)† | 12 (52.2) | 107.0 (48.5-178.6) | 11 (47.8) | 10 (43.4) | 2 (8.7) |
| 3-5 | 19 (6/13) | 18 (94.7) | 288.4 (80.9-1681.8) | 13 (68.4) | 134.0‡ (32.5-328.7) | 7 (37.8) | 10 (52.6) | 2 (10.5) |
| 6-9 | 18 (11/7) | 18 (100) | 361.1 (89.2-2200.2)¶ | 16 (88.9) | 103.6 (33.1-219.7) | 8 (47.0) | 7 (41.2) | 2 (11.8) |
| 10-12 | 20 (10/10) | 20 (100) | 215.4 (43.4-1693.6) | 18 (90.0) | 119.3§ (37.2-359.5) | 8 (44.4) | 8 (44.4) | 2 (11.1) |
| 13-15 | 23 (10/13) | 23 (100) | 252.6 (51.5 −1057.9) | 16 (70.0) | 114.6 (29.7-193.4) | 11 (47.8) | 10 (43.4) | 2 (8.7) |
| 16-19 | 23 (11/12) | 23 (100) | 177.6 (61.2-678.1) | 18 (78.2) | 99.9 (23.9-195.2) | 10 (47.6) | 8 (38.1) | 3 (14.3) |
| 20-25 | 22 (11/11) | 22 (100) | 252.5 (81.5-828.4) | 19 (86.4) | 93.9 (27.6-171.7) | 11 (52.4) | 8 (38.1) | 2 (9.5) |
| 26-39 | 22 (13/9) | 22 (100) | 165.9 (39.0-968.4) | 19 (86.4) | 88.8 (24.9-272.7) | 14 (73.7) | 3 (15.7) | 2 (10.5) |
| 40-49 | 21 (10/11) | 21 (100) | 191.2 (53.5-735.2) | 13 (61.9) | 73.4 (24.0-183.2) | 14 (70.0) | 4 (20.0) | 2 (10.0) |
| Total | 191 (91/100) | 187 (97.9) | 252.6 (39-2200.1) | 145 (75.9) | 101.8 (23.9-359.5) | 94 (51.9) | 68 (37.6) | 19 (10.5) |
NKG2C genotypes were obtained from a total of 181 individuals.
Significantly higher anti-HCMV IgG titers compared with 16- to 19-year-olds and all groups older than 26 years; P < .05, analysis of variance.
Significantly elevated anti-EBV nuclear antigen IgG titers compared with all groups older than 16 years.
Significantly higher anti-HCMV IgG titers compared with all groups older than 16 years; P < 0.01, analysis of variance.
Significantly elevated anti-EBV nuclear antigen IgG titers compared with all groups older than 20 years.